decitabine
decitabine: 33 clinical trials tracked.
decitabine evidence translation
What we can confirm
33 tracked trials
What it means
What to watch
Prepared research question
What is verified about decitabine, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence4 indications · 9 study sponsors
Related indications
Clinical Trials (33)showing 10 most recent
Research for Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Myelodysplastic Syndrome (MDS)
Primary endpoint: Treatment related-adverse events counting
A Phase 1 Study of Oral Cedazuridine and Decitabine Combination (ASTX727, NSC# 820631) and Filgrastim as Maintenance Therapy Post-Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
Primary endpoint: Maximum tolerated dose
A Phase I Study of ATRN-119, an ATR Inhibitor, in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDS
Primary endpoint: Number and grade of treatment-emergent adverse events (TEAEs) as assessed via CTCAE v6.0
Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated/Deleted AML Patients
Primary endpoint: Phase 2 Dose Level determination
A Phase I/IIA Study Evaluating the Safety and Efficacy of NY-ESO-1TCR/dnTGFBRII Engineered T Cells in Combination With Decitabine in Subjects With Recurrent or Treatment Refractory Ovarian Cancer and Other Advanced Malignancies
Primary endpoint: To evaluate autologous in the number of participants with treatment-related adverse events.
A Phase 2 Trial Investigating the Addition of Pacritinib to a Hypomethylating Agent as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant in Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms
Primary endpoint: Number of patients who receive hematopoietic stem cell transplant
FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia
Primary endpoint: Dose-limiting toxicities (DLTs)
Phase I/II Study of Leflunomide in Combination With Decitabine for Treatment of Relapsed or Refractory (R/R) Myelodysplastic Syndromes (MDS)
Primary endpoint: Percentage of incidences of regimen limiting toxicities (RLTs)
Discontinuation of Hypomethylating Agent and Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) Who Have Achieved Negative Measurable Residual Disease (MRD)
Primary endpoint: Rates of Complete Response (CR)/Complete Response with incomplete hematologic recovery (CRi)
Phase 1b/2 Study of Decitabine and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor Olutasidenib
Primary endpoint: Safety and adverse events (AEs)